A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

Study summary

The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMEDI4736 and Tremelimumab

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 31, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?69 U.S. locations

Locations may change over time.

Who runs it?MedImmune LLC

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: MedImmune LLC
Interventions being studied: Drug: MEDI4736; Drug: Tremelimumab; Drug: tremelimumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Age ≥ 18 years 2. Advanced non-small cell lung cancer 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 4. Adequate organ and marrow function

Reasons someone may not be able to joinExclusion criteria

1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment 2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs 3. Active or prior documented autoimmune disease within the last 2 years.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Research SiteBirmingham, Alabama
Research SiteTucson, Arizona
Research SiteLos Angeles, California
Research SiteLos Angeles, California
Research SiteSan Francisco, California
Research SiteAurora, Colorado
Research SiteNew Haven, Connecticut
Research SiteNewark, Delaware
Research SiteTampa, Florida
Research SiteIndianapolis, Indiana
Research SiteBaltimore, Maryland
Research SiteBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 31, 2019. Always confirm current availability with the study team.

View original record ↗